BCM
GTHX

Bayesian Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bayesian Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,558
Closed -$79.2K – 1122
2023
Q1 		$79.2K Buy
+29,558
New +$142K 0.01% 697
2022
Q3 		– Sell
-23,800
Closed -$118K – 1077
2022
Q2 		$118K Buy
+23,800
New +$132K 0.02% 676

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's GTHX Position: Q2 2023 in Review

Bayesian Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2023, closing a stake of 29,558 shares — an estimated $79.2K sold.

Bayesian Capital Management first reported a position in GTHX in Q2 2022 and held it in 2 quarters. The position peaked at $118K in Q2 2022. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

  • Bayesian Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 29,558 G1 Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $79.2K.
  • Bayesian Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Bayesian Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $118K in Q2 2022.
  • 80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Bayesian Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.